RTW Investments LP Takes Position in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

RTW Investments LP acquired a new stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund acquired 50,000 shares of the company's stock, valued at approximately $800,000.

Several other institutional investors have also recently bought and sold shares of CNTA. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Centessa Pharmaceuticals by 47.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company's stock valued at $40,000 after buying an additional 826 shares during the period. GAMMA Investing LLC increased its holdings in Centessa Pharmaceuticals by 103.1% in the third quarter. GAMMA Investing LLC now owns 2,972 shares of the company's stock valued at $48,000 after purchasing an additional 1,509 shares during the last quarter. Quarry LP grew its position in shares of Centessa Pharmaceuticals by 47.8% during the 2nd quarter. Quarry LP now owns 9,608 shares of the company's stock worth $87,000 after buying an additional 3,108 shares during the period. Sandia Investment Management LP bought a new stake in shares of Centessa Pharmaceuticals in the 2nd quarter valued at about $90,000. Finally, Fred Alger Management LLC acquired a new stake in shares of Centessa Pharmaceuticals in the 2nd quarter valued at approximately $99,000. Institutional investors own 82.01% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. B. Riley assumed coverage on Centessa Pharmaceuticals in a research report on Thursday, September 19th. They issued a "buy" rating and a $33.00 price objective for the company. Guggenheim boosted their target price on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a "buy" rating in a research report on Friday, November 15th. BMO Capital Markets boosted their price objective on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an "outperform" rating in a report on Monday, September 16th. Oppenheimer reiterated an "outperform" rating and issued a $14.00 price target on shares of Centessa Pharmaceuticals in a research note on Wednesday, August 14th. Finally, Morgan Stanley upgraded Centessa Pharmaceuticals from an "equal weight" rating to an "overweight" rating and raised their price objective for the stock from $11.00 to $26.00 in a research note on Thursday, September 19th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $25.83.

Centessa Pharmaceuticals Price Performance

Shares of CNTA stock traded up $0.15 during trading hours on Thursday, reaching $17.31. The company's stock had a trading volume of 66,569 shares, compared to its average volume of 416,429. Centessa Pharmaceuticals plc has a fifty-two week low of $6.15 and a fifty-two week high of $18.74. The firm's 50 day simple moving average is $16.32 and its 200-day simple moving average is $12.86. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $2.28 billion, a price-to-earnings ratio of -11.22 and a beta of 1.52.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, beating analysts' consensus estimates of ($0.42) by $0.05. Sell-side analysts forecast that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Insiders Place Their Bets

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 25,000 shares of the business's stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $15.00, for a total transaction of $375,000.00. Following the completion of the sale, the insider now directly owns 223,369 shares of the company's stock, valued at approximately $3,350,535. The trade was a 10.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Saurabh Saha sold 2,592 shares of the firm's stock in a transaction on Wednesday, October 23rd. The shares were sold at an average price of $15.32, for a total value of $39,709.44. Following the transaction, the chief executive officer now owns 630,661 shares in the company, valued at approximately $9,661,726.52. This trade represents a 0.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 375,128 shares of company stock valued at $6,148,522. 11.59% of the stock is currently owned by company insiders.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.